Comparative Pharmacology
Head-to-head clinical analysis: EXTENDED PHENYTOIN SODIUM versus FELBATOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXTENDED PHENYTOIN SODIUM versus FELBATOL.
EXTENDED PHENYTOIN SODIUM vs FELBATOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, reducing repetitive firing of action potentials, and decreasing synaptic transmission.
Felbamate is a GABA receptor agonist and modulates NMDA receptor activity, though its exact mechanism is not fully understood. It appears to enhance GABA-mediated inhibition and inhibit voltage-gated sodium channels, reducing neuronal excitability.
Oral: 100 mg three times daily; intravenous: 10-20 mg/kg loading dose at a maximum rate of 50 mg/min, then 100 mg every 6-8 hours maintenance.
1200-3600 mg/day orally in 3-4 divided doses; initial titration recommended.
None Documented
None Documented
22–32 hours (mean 24 hours) in adults, dose-dependent due to saturable metabolism; may exceed 60 hours at high concentrations.
20-23 hours; steady state reached within 3-5 days; may be prolonged in hepatic impairment.
Primarily hepatic metabolism (CYP2C9/CYP2C19), with <5% excreted unchanged renally. Fecal excretion accounts for minor elimination.
Renal: 40-50% unchanged; Hepatic metabolism accounts for ~50% with glucuronidation and oxidation; minimal biliary/fecal excretion (<5%).
Category D/X
Category C
Anticonvulsant
Anticonvulsant